| Dr Paul Francis O'kane, DDS | |
|
726 Main St, Ackley, IA 50601-1538 | |
| (641) 847-2330 | |
| (641) 847-2330 |
| Full Name | Dr Paul Francis O'kane |
|---|---|
| Gender | Male |
| Speciality | Dentist |
| Location | 726 Main St, Ackley, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841604378 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | 09085 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul Francis O'kane, DDS 726 Main St, Ackley, IA 50601-1538 Ph: (641) 847-2330 | Dr Paul Francis O'kane, DDS 726 Main St, Ackley, IA 50601-1538 Ph: (641) 847-2330 |
News Archive
When surgeons operate to remove a tumor, determining exactly where to cut can be tricky. Ideally, the entire tumor should be removed while leaving a continuous layer of healthy tissue, but current techniques for locating the tumors during surgery are imprecise. Now a multidisciplinary team from the University of California, San Diego, is developing an alternate means of precisely tagging breast cancer tumors for removal or targeted destruction.
Scientists are reporting development and successful initial laboratory tests on the key ingredient for a much-needed vaccine to help individuals addicted to heroin abstain from the illicit drug. Their study appears in ACS' Journal of Medicinal Chemistry.
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
Bionovo, Inc. has announced the online publication of a peer-reviewed article in the journal, Menopause, reporting Menerba (formerly MF101) is well tolerated, safe and effective for the treatment of vasomotor symptoms (hot flashes and night sweats) associated with menopause.
In related news, Sen. Lisa Murkowski, R-Alaska, is reportedly having "voter's remorse" regarding her decision last week to vote for similar Senate legislation - the Blunt amendement.
› Verified 5 days ago